Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015.
Yamazaki Y, Naganuma A, Arai Y, Takeuchi S, Kobayashi T, Takakusagi S, Hatanaka T, Hoshino T, Namikawa M, Hashizume H, Takizawa D, Ohyama T, Suzuki H, Horiguchi N, Takagi H, Sato K, Kakizaki S, Kusano M, Nagashima S, Takahashi M, Okamoto H, Yamada M. Yamazaki Y, et al. Among authors: namikawa m. Hepatol Res. 2017 Apr;47(5):435-445. doi: 10.1111/hepr.12765. Epub 2016 Jul 27. Hepatol Res. 2017. PMID: 27322051
Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: namikawa m. Hepatol Res. 2020 Mar;50(3):303-312. doi: 10.1111/hepr.13462. Epub 2019 Dec 19. Hepatol Res. 2020. PMID: 31750974
Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.
Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Takaoka Y, et al. Among authors: namikawa m. Hepatol Res. 2021 Jan;51(1):51-61. doi: 10.1111/hepr.13576. Epub 2020 Oct 20. Hepatol Res. 2021. PMID: 33021009
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: namikawa m. Intern Med. 2021;60(19):3061-3070. doi: 10.2169/internalmedicine.6591-20. Epub 2021 Oct 1. Intern Med. 2021. PMID: 34602520 Free PMC article.
Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study.
Suzuki Y, Naganuma A, Hoshino T, Hatanaka T, Ueno T, Namikawa M, Takizawa D, Arai H, Suzuki H, Takagi H, Tojima H, Yamazaki Y, Sato K, Kakizaki S, Uraoka T. Suzuki Y, et al. Among authors: namikawa m. Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):57-63. doi: 10.51821/84.1.357. Acta Gastroenterol Belg. 2021. PMID: 33639694 Free article.
Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Hatanaka T, Kakizaki S, Uehara D, Nagashima T, Ueno T, Namikawa M, Saito S, Hosonuma K, Suzuki H, Naganuma A, Takagi H, Sato K, Uraoka T. Hatanaka T, et al. Among authors: namikawa m. Intern Med. 2019 Jul 1;58(13):1835-1844. doi: 10.2169/internalmedicine.1594-18. Epub 2019 Mar 28. Intern Med. 2019. PMID: 30918170 Free PMC article.
61 results